Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013

CSO to Present Data on Using the SURE CHO-Mplus Combinatorial Library to Address a Broad Range of Protein Production Bottlenecks

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Selexis Chief Scientific Officer - Pierre-Alain Girod, Ph.D.

Selexis Chief Scientific Officer - Pierre-Alain Girod, Ph.D.

Utilizing the CHO-M genome and transcriptome, we have engineered a combinatorial CHO cell library to address a broad range of these production bottlenecks.

Geneva, Switzerland (PRWEB) July 31, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company will present data on the SURE CHO-Mplus™ Library at the Bioprocessing Summit being held August 19 – 23 at the Renaissance Boston Waterfront Hotel in Boston, Massachusetts. Selexis’ chief scientific officer, Pierre-Alain Girod, PhD, will present, “A CHO-M Cell Combinatorial Library for the Improved Selection of Recombinant Protein Production Clones,” on Wednesday, August 21 at 11:45 AM as part of the Cell Line Development tract.

Additionally, a poster presentation with data from the recently launched SURE CHO-Mplus™ Library, “CHO Cell Library for the Selection of Improved Recombinant Therapeutic Protein Production,” is scheduled to be presented at the conference. The poster presentation will discuss new solutions that address a broad range of recombinant protein secretion issues.

Presentation Abstract:    
With some proteins, optimal productivity requires more than elevated transcription. Metabolic limitations, trafficking backlogs, improper folding and altered post-translational modifications can all effect output. Utilizing the CHO-M genome and transcriptome, we have engineered a combinatorial CHO cell library to address a broad range of these production bottlenecks.

Poster Abstract:
In an effort to improve product yield of mammalian cell lines, we have previously demonstrated that our proprietary DNA elements, Selexis Genetic Elements (SGEs), increase the transcription of a given transgene, thus boosting the overall expression of a therapeutic protein drug in mammalian cells.

However, there are additional cellular bottlenecks, notably in the molecular machineries of the secretory pathways. Most importantly, mammalian cells have some limitations in their intrinsic capacity to manage high level of protein synthesis as well as folding recombinant proteins. These bottlenecks often lead to increased cellular stress and, therefore, low production rates.

Dr. Girod and the company’s VP of business development, Andrew Sandford, will be available for questions at the Selexis Booth 7 from August 19 - 23. Please see conference website for complete schedule.

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

# # #


Contact

Follow us on: Contact's Facebook Contact's Twitter

Attachments

Leveraging the SURE CHO-M Genome™ and transcriptome, Selexis engineered the combinatorial SURE CHO-Mplus Library™ to address a broad range of protein production bottlenecks, including metabolic limitations, trafficking backlogs, improper folding and alter Selexis SURE CHO-Mplus™ Library

SURE CHO-Mplus Library™ addresses a broad range of protein production bottlenecks


.  Selexis’ SUREtechnology Platform™ can be applied from early drug discovery to cGMP manufacturing, resulting in faster, more reliable, higher-expressing mammalian cell lines Selexis

Selexis